Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $8 from $13 and keeps a Buy rating on the shares after the company blamed its Q3 revenue shortfall on its DTC segment, Medicx. The stock was down 15% in after-market trading, consistent with estimate revisions, notes the firm, which expects the stock to be range-bound pending stabilization of the DTC segment and better visibility on 2025 growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX: